Academic research collaboration

SciLifeLab actively supports and participates in national and international research networks. The External Relations Office focus on identifying models for multi-stakeholder collaborations and connecting the local and national innovation system closer to the research infrastructure, as well as engaging in activities aimed to stimulate multi- and cross sector interactions.

SciLifeLab, learn more about our developemt from the 10th anniversary web site

The people

More than 1000 affiliated group leaders, fellows, students and employees to connect with. SciLifeLab infrastructure unit scientists, fellows and associated PIs have broad international networks within their respective fields and are ready to make contact. 

SciLifeLab Research Community
Publication database

Examples of national and international initiatives

SciLifeLab Capabilities

SciLifeLab’s capabilities combine infrastructure technology with expertise on Planetary Biology, Precision Medicine, and Pandemic Laboratory Preparedness.

Data Driven Life Science (DDLS)

The SciLifeLab and Wallenberg National Program on Data-Driven Life Science (DDLS) mission is to recruit and train the next generation of life scientists in line with life science research continuously becoming more data-dependent. 

The European Molecular Biology Laboratory (EMBL) 

EMBL and SciLifeLab share the same overarching goals to advance science for the benefit of healthcare, biodiversity and the environment.

The Science and SciLifeLab Prize

The Science and SciLifeLab Prize for Young Scientists is an initiative rewarding scientists at an early stage of their careers.


ELIXIR unites Europe’s leading life science organisations in managing and safeguarding the increasing volume of data being generated by publicly funded research.

Research Community Programs (RCPs) 

SciLifeLab supports seven Research Community Programs (RCPs) – networks that connect top researchers with each other and with the SciLifeLab infrastructure.


RIKEN is Japan’s largest comprehensive research institution and the collaboration includes joint annual RIKEN-SciLifeLab symposia alternating between the sites since 2014, research collaborations and visits. Example of research collaboration: New method sheds light on the role of RNA in chromatin regulation.
Each symposium of the series is centered on one specific topic. Topics from previous years are: Molecular Imaging and Genomics (2014), Structural Biology for Drug Discovery (2015), Decoding Health and Disease with a) Imaging & Disease, b) RNA & Disease, c) Single, Rare and Stem cells & Disease (2016), Life Science Frontiers in Health, Disease and Aging, with sessions a) Gene Expression in Disease and Aging, b) Neural Function, Disease and Therapy, c) Molecular Aspects of Health, Disease and Aging, d) Visualizing Health, Disease and Aging, e) Molecular Network Control (2017), Artificial Intelligence meet Life Sciences (2018), and Biomedical Data for Artificial Intelligence (2019, 2020).

Upcoming event: The 8th RIKEN-KI-SciLifeLab Symposium, 2022-10-20 Preparing for the next pandemic.

Translating academic drug discovery projects to industry 

The drug discovery and development platform (DDD) platform makes use of fundamental academic research discoveries across the country and validates these as drug discovery targets and creates lead molecules that would provide attractive future investment as opportunities within the private sector. Over the past 4 years, DDD has successfully developed therapeutic discoveries with numerous academic groups across the country. Several projects have been out-licensing to industry or established as new spin-off companies. The combination of tools available at SciLifeLab units provide excellent opportunities for drug discovery and development, at different points in the route to new treatments. With its mission to support researchers in developing prototypes for new drugs, The DDD platform is focused on providing state-of-the-art drug discovery technologies to scientists across the country.


Last updated: 2022-11-14

Content Responsible: Josefin Lundgren Gawell(